Registry of Pre-mixed Solutions in Critically Ill Patients on the Continuous Renal Replacement Therapy

Registry of Pre-mixed Solutions in Critically Ill Patients on the Continuous Renal Replacement Therapy (PrioR): a Multicenter, Prospective Real-world

This is a multicenter, prospective, registry study. By collecting relevant demographic information and clinical data of patients receiving continuous renal replacement therapy (CRRT) with pre-mixed solutions, the clinical applicability of pre-mixed solutions will be evaluated in critically ill patients in real-world clinical settings.

This study will be carried out in approximately 10 study sites in China. Patient data will be collected to evaluate the clinical applicability of pre-mixed solutions.

Treatment observation period: From initiation of the first CRRT with sponsored pre-mixed solutions to cessation of the pre-mixed solutions. The duration of this period can be up to 10 days.

Follow-up period: from the cessation of sponsored pre-mixed solutions to Day 30 after starting treatment with the pre-mix solutions.

Inclusion Criteria:

• 18 ≤ age < 80 years old.
• Patients admitted to the intensive care unit (ICU) and in need of CRRT.
• Patients are willing to receive CRRT with at least one of three pre-mixed solutions:

Regiocit, Biphozyl, or Prismasol 2.

Exclusion Criteria:

• Patients with chronic kidney failure who are receiving maintenance dialysis.
• Patients expected to require the premixed solution for less than 24 hours.
• Patients who are allergic or have contraindications to components of pre-mixed solutions, as determined by the investigators.
• Patients who have participated in other interventional studies within the last 30 days.
• Patients who are pregnant, breastfeeding, or abortus imminence.